Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring

Pérez-Callejo, David; Romero, Atocha; Provencio, Mariano; Torrente, María

doi:10.21037/tlcr.2016.10.07

Cited by 89 publications

(82 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Baseline CTC counts of over 5/7.5 mL were associated with shorter progression free survival (PFS) and OS in patients with NSCLC (11). The prognostic role of CTC detection has also been shown in surgically resected NSCLC (10). Furthermore, the prognostic significance of CTCs in lung cancer was demonstrated in a meta-analysis of 20 trials comprising 1,576 NSCLC patients, which revealed a significant association between the presence of CTCs and decreased disease-free survival (DFS) and decreased OS (12).…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

See 1 more Smart Citation

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance. As lung tumor tissue can be difficult to obtain without invasive and potentially risky procedures, it is difficult to monitor treatment response with serial tissue biopsies. Development of non-invasive but reliable blood based tumor markers has become an important research area. In this review, we focus on the following circulating biomarkers that have been identified in recent years: circulating tumor cells (CTCs); circulating cell-free nucleic acids, such as circulating tumor DNA (ctDNA) and microRNA (miR); and other biomarkers such as genomic and proteomic features. These biomarkers not only have prognostic values, but also can help guild treatment decisions by monitoring tumor burden, detecting minimal residual disease and/or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.

show abstract

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

“…The presence of CTCs has been associated with poor outcomes in advanced stage cancer patients (8)(9)(10). With the use of the CellSearch system, CTC number was a strong predictor of overall survival (OS) in a cohort of 101 patients with non-small cell lung cancer (NSCLC) (11).…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Platelet mRNA profiles showed downregulation of numerous genes, including many associated with translation, IL-signaling, protein synthesis, and immunity, and upregulation of cancer-associated, metabolic, cytoskeletal, and platelet-related genes (Best et al, 2015). EML4-ALK rearrangements in non-small-cell lung cancer were detectable by RT-PCR in platelets, and this correlated with poor prognosis (Nilsson et al, 2015), suggesting TEP may be a promising source for liquid biopsy (Feller and Lewitzky, 2016; Perez-Callejo et al, 2016). …”

Section: Platelets and Cancer Progressionmentioning

confidence: 99%

Cancer and Thrombosis: The Platelet Perspective

Meikle

Kelly

Garg

et al. 2017

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Platelets are critical to hemostatic and immunological function, and are key players in cancer progression, metastasis, and cancer-related thrombosis. Platelets interact with immune cells to stimulate anti-tumor responses and can be activated by immune cells and tumor cells. Platelet activation can lead to complex interactions between platelets and tumor cells. Platelets facilitate cancer progression and metastasis by: (1) forming aggregates with tumor cells; (2) inducing tumor growth, epithelial-mesenchymal transition, and invasion; (3) shielding circulating tumor cells from immune surveillance and killing; (4) facilitating tethering and arrest of circulating tumor cells; and (5) promoting angiogenesis and tumor cell establishment at distant sites. Tumor cell-activated platelets also predispose cancer patients to thrombotic events. Tumor cells and tumor-derived microparticles lead to thrombosis by secreting procoagulant factors, resulting in platelet activation and clotting. Platelets play a critical role in cancer progression and thrombosis, and markers of platelet-tumor cell interaction are candidates as biomarkers for cancer progression and thrombosis risk.

show abstract

“…Three years later, the association of CTC number and patient outcome was demonstrated in metastatic breast cancer using the CellSearch ® platform (Janssen Diagnostics, LLC, Raritan, NJ, USA), a semi-automated system that immunomagnetically enriches epithelial cell adhesion molecule (EpCAM)-positive CTCs and enumerates them as (EpCAM+)CK+DAPI+CD45− cells (6). Since then, substances that could be extracted from blood, serum and plasma have been included in the concept of liquid biopsy, such as circulating cell-free nucleic acids (DNA, RNA or microRNAs), and exosomes (7). Today, the term also incorporates several other biological materials obtained from almost all body fluids (urine, pleural effusion, ascites, etc.)…”

Section: Review Articlementioning

confidence: 99%

“…Several studies investigated the association of ctDNA levels and clinical outcome in lung cancer patients. However, since the absolute ctDNA amount is poorly significant as a diagnostic tool, the attention has focused on real-time monitoring of tumorassociated mutations for tracking the response to target therapies and/or the early onset of drug resistance (7). In this context, recent techniques such as digital PCR (dPCR) and next generation sequencing (NGS) have overcome the limit of sensitivity of traditional methods, such as Sanger sequencing, allowing the detection of ctDNA even if it represents a poor fraction of the total cfDNA (<1.0%) (23).…”

Section: Ctcs and Circulating Tumor Microemboli (Ctm)mentioning

confidence: 99%